Litmys Launches to Transform Drug and Device Development Risk Assessment, Assessing a Life Science Product’s Commercial Success Before Phase 3
Santa Fe, New Mexico — November 24, 2025 — Litmys, a newly launched life sciences consulting firm, today unveiled its groundbreaking approach to drug development risk assessment, an evidence-driven model that enables pharmaceutical, biotechnology, diagnostic, and medical device companies to make earlier, smarter, and commercially informed R&D investment decisions.
Litmys has developed a proprietary, FICO-style predictive scoring model (known as RAMPx™) that evaluates and assesses the strength of a product’s value proposition and forecasts its likelihood of real-world commercial success before companies commit to costly Phase 3 clinical trials. Drawing on 12 proven factors that drive product adoption, RAMPx provides a holistic evidence-based assessment of an asset’s strengths, weaknesses, differentiating attributes, and areas requiring remediation. This enables life science companies to reduce risk, prioritize the highest-value assets, and allocate R&D capital with greater precision.
Tackling the Industry’s Most Urgent R&D Challenge
Drug development remains one of the riskiest and most financially demanding undertakings in the life sciences industry. Today:
50% of products entering Phase 3 clinical trials fail.
Of those that succeed, approximately 50% underperform commercially thereby missing revenue expectations.
Every failed Phase 3 asset results in an estimated $160M–$300M+ in wasted spend.
Industry-wide R&D ROI hovers at ~5.6%, according to leading market analyses.
Litmys is built to change this equation
“Companies routinely enter Phase 3 of a clinical trial without a clear picture of whether a drug’s commercial story is strong enough to justify the investment,” said Harris Kaplan, Managing Partner at Litmys. “Our model gives leaders visibility they’ve never had before, commercial foresight ahead of the most capital-intensive stage of development.”
A New Standard for R&D Decision-Making
Litmys’ RAMPx model helps life sciences organizations:
Identify commercially weak assets early, before costly late-stage trials.
Reduce wasteful R&D spending and improve overall portfolio ROI.
Shift risk earlier in development, when adjustments are easier and far less expensive.
Prioritize assets with real-world commercial adoption potential, ensuring resources are deployed into programs with the highest likelihood of delivering value.
By providing an objective, data-driven prediction of commercial viability, Litmys empowers leaders to make more confident go/no-go decisions and chart development paths grounded in marketplace realities, not internal assumptions.
Transforming How Life Science Leaders Allocate Capital
“Pharma and biotech leaders deserve a tool that connects early-stage development with late-stage commercial outcomes,” said Kaplan. “Litmys is redefining how organizations forecast success and allocate billions in R&D investment. This is a new era of accountability, clarity, and commercial alignment in life sciences product development.”
# # #
About Litmys
Litmys is a life sciences consulting firm specializing in drug and device development risk assessments and commercial readiness analytics. Its proprietary predictive scoring model provides early insight into a therapeutic asset’s real-world commercial viability, enabling life sciences companies to reduce costly failure rates, strengthen R&D pipeline ROI, and make investment decisions with confidence. Litmys is headquartered in Santa Fe, New Mexico, with an additional office in Minneapolis, Minnesota. Learn more at www.litmys.com